Spectral Medical Inc. (EDT.TO)
| Previous close | 0.5100 |
| Open | 0.4900 |
| Bid | 0.4900 x 0 |
| Ask | 0.4950 x 0 |
| Day's range | 0.4600 - 0.5000 |
| 52-week range | 0.2600 - 0.6700 |
| Volume | |
| Avg. volume | 54,946 |
| Market cap | 136.903M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 19 Dec 2011 |
| 1y target est | N/A |
- GlobeNewswire
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 19, 2024 (the "Circular") to its Shareholders were approved. Results of t
- GlobeNewswire
Spectral Medical Inc. Announces Closing of Approximately C$8.5 Million Convertible Notes Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to confirm the closing of previously announced offering of 9% convertible notes of the Company at a price of US$1,000 per convertible no
- GlobeNewswire
Spectral Medical Announces First Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the fi
